 | Up a level |
König, D; Savic Prince, S; Hayoz, S; Zens, P; Berezowska, S; Jochum, W; Stauffer, E; Braunersreuther, V; Trachsel, B; Thierstein, S; Mark, M; Schmid, S; Curioni-Fontecedro, A; Addeo, A; Opitz, I; Guckenberger, M; Früh, M; Betticher, D C; Ris, H-B; Stupp, R; ... (2023). Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14. ESMO open, 8(4), p. 101595. BMJ 10.1016/j.esmoop.2023.101595
Schmid, S; Jochum, W; Padberg, B; Demmer, I; Mertz, K D; Joerger, M; Britschgi, C; Matter, M S; Rothschild, S I; Omlin, A (2022). How to read a next-generation sequencing report-what oncologists need to know. ESMO open, 7(5), p. 100570. BMJ 10.1016/j.esmoop.2022.100570
Helbling, B; Jochum, W; Stamenic, I; Knöpfli, M; Cerny, A; Borovicka, J; Gonvers, JJ; Wilhelmi, M; Dinges, S; Müllhaupt, B; Esteban, A; Meyer-Wyss, B; Renner, EL; Swiss, Association for the Study of the Liver (SASL) (2006). HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon alpha-2a and ribavirin. Journal of viral hepatitis, 13(11), pp. 762-9. Oxford: Blackwell Science 10.1111/j.1365-2893.2006.00753.x
